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ABSTRACT
Background. Cocaine use disorder (CUD) is a complex health condition, especially
when it is accompanied by comorbid psychiatric disorders (dual diagnosis). Dual
diagnosis is associated with difficulties in the stratification and treatment of patients.
One of the major challenges in clinical practice of addiction psychiatry is the lack
of objective biological markers that indicate the degree of consumption, severity of
addiction, level of toxicity and response to treatment in patients with CUD. These
potential biomarkers would be fundamental players in the diagnosis, stratification,
prognosis and therapeutic orientation in addiction. Due to growing evidence of the
involvement of the immune system in addiction and psychiatric disorders, we tested
the hypothesis that patients with CUD in abstinence might have altered circulating
levels of signaling proteins related to systemic inflammation.
Methods. The study was designed as a cross-sectional study of CUD treatment-seeking
patients. These patients were recruited from outpatient programs in the province of
Malaga (Spain). The study was performed with a total of 160 white Caucasian subjects,
whowere divided into the following groups: patients diagnosedwith CUD in abstinence
(N = 79, cocaine group) and matched control subjects (N = 81, control group).
Participants were clinically evaluated with the diagnostic interview PRISM according to
the DSM-IV-TR, and blood samples were collected for the determination of chemokine
C-C motif ligand 11 (CCL11, eotaxin-1), interferon gamma (IFNγ), interleukin-4
(IL-4), interleukin-8 (IL-8), interleukin-17α (IL-17α), macrophage inflammatory
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protein 1α (MIP-1α) and transforming growth factor α (TGFα) levels in the plasma.
Clinical and biochemical data were analyzed in order to find relationships between
variables.
Results. While 57% of patients with CUD were diagnosed with dual diagnosis,
approximately 73% of patients had other substance use disorders. Cocaine patients
displayed greater cocaine symptom severity when they were diagnosed with psychiatric
comorbidity. Regarding inflammatory factors, we observed significantly lower plasma
levels of IL-17α (p< 0.001), MIP-1α (p< 0.001) and TGFα (p< 0.05) in the cocaine
group compared with the levels in the control group. Finally, there was a significant
primary effect of dual diagnosis on the plasma concentrations of TGFα (p< 0.05) in
the cocaine group, and these levels were lower in patients with dual diagnoses
Discussion. IL-17α, MIP-1α and TGFα levels are different between the cocaine and
control groups, and TGFα levels facilitate the identification of patients with dual
diagnosis. Because TGFα reduction is associated with enhanced responses to cocaine
in preclinical models, we propose TGFα as a potential biomarker of complex CUD in
humans.
Subjects Cognitive Disorders, Neurology, Psychiatry and Psychology
Keywords Cocaine use disorders, Cytokines, Dual diagnosis
INTRODUCTION
Cocaine use disorder (CUD) constitutes a highly complex health problem involving not only
biological changes in the brain but also a variety of social and environmental aspects (Tomasi
et al., 2015). The chronic use of cocaine is often accompanied by medical issues, including
circulatory diseases and comorbid psychiatric conditions (González-Saiz et al., 2014;
Verdejo-Garcia et al., 2015;Chibungu et al., 2016). Dual diagnosis or co-occurring disorders
describes the presence of both a mental health and a substance use disorder, and the dual
nature of this condition complicates the diagnosis and therapeutic outcomes in CUD
because many of the patients do not respond to classical pharmacological approaches (Tor-
rens, Gilchrist & Domingo-Salvany, the PsyCoBarcelona Group, 2011; Álvarez et al., 2013).
Moreover, the quality of life of these patients is severely impaired (Chahua et al., 2015).
To improve the therapeutic process in addiction, one of the challenges is to identify
biological markers that might aid in objectively determining the degree of consumption,
severity of addiction, level of toxicity and response to treatment in patientswithCUD(Pavón
et al., 2013; Araos et al., 2015). These potential biomarkers would be fundamental players
in the diagnosis, stratification, prognosis and therapeutic orientation in addictions. Several
attempts have been made to identify these possible biomarkers by exploring accessible
signaling compartments (i.e., blood) or functional neuropsychological tests. Among these
attempts, recent studies have identified circulating factors involved in immune function as
potential biomarkers in CUD and other substance use disorders (Araos et al., 2015;Moreira
et al., 2016; García-Marchena et al., 2017a). These and other studies have demonstrated
that abused drugs interact with the immune system and alter signaling and gene expression
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involved in the immune response, which these effects contribute to various aspects of
addiction (Cui, Shurtleff & Harris, 2014).
More specifically, cocaine abuse results in increased pro-inflammatory signaling
throughout the brain (Cearley et al., 2011; Coller & Hutchinson, 2012); however, the
mechanism is unknown. These alterations are also found in some plasma circulating
chemokines and cytokines (Araos et al., 2015), indicating that alterations in pro- and
anti-inflammatory factors may serve as potential biomarkers of an inflammatory state in
the central nervous system (CNS). In fact, this systemic inflammation has been recently
proposed to be a mechanism that facilitates dopamine signaling in the brain, which
contributes to the addiction cycle (Petrulli et al., 2017).
The fact that the immune system modifies brain functions related to addiction and
the concurrent participation of reward modulatory systems in psychiatric disorders
open the possibility of establishing a link between inflammation, neuropsychiatric
diseases and addictive disorders (Stertz, Magalhaes & Kapczinski, 2013). Comorbid mental
health and substance use disorders are usually present in more than 50% of cocaine- or
alcohol-addicted patients (Vergara-Moragues et al., 2012; García-Marchena et al., 2017b).
Convergence of neuroinflammation, stress and addiction in neural substrates of mental
diseases could help us to understand this complex association. Stressful experiences may
model the immune system, modifying the release and signaling of cytokines involved in
inflammation (Slavich, 2016). In addition, several studies indicate that the inflammatory
processes could actively influence the CNS and that this would generate changes in
the behavior of the subjects (Irwin & Miller, 2007). As an example, neuroinflammation
and alterations in neurogenesis are clear substrates of mood disorders (Goldstein et al.,
2009), and both processes are clearly affected by abused drugs (Castilla-Ortega et al., 2016;
Neupane, 2016).
This research is the continuation of a previous study in patients with CUD (Araos et
al., 2015); in the present study, we also analyzed the inflammatory signaling factors in the
blood of patients addicted to cocaine to explore the relationships between the expression of
circulating agents related to neuroinflammation and neurogenesis (cytokines, chemokines
and growth factors) and variables associated with CUD and dual diagnosis. The selected
molecules in these two studies were chosen according to an exhaustive bibliographic search.
The inflammatory signals examined in the current study were chemokine C-C motif
ligand 11 (CCL11, eotaxin-1), interferon gamma (IFNγ), interleukin-4 (IL-4), interleukin-
8 (IL-8), interleukin-17α (IL-17α), macrophage inflammatory protein 1α (MIP-1α) and
transforming growth factor α (TGFα).
The main goal of the present study was to evaluate the plasma concentrations of
cytokines, chemokines and growth factor in a cohort of CUD patients in abstinence
compared to population controls. Variables related to CUD, such as the duration of
problematic cocaine use, abstinence length, cocaine addiction severity and dual diagnosis,
were also examined in relation to these molecules.
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MATERIALS AND METHODS
Study design and recruitment
A cross-sectional study was conducted on patients diagnosed with CUD seeking treatment
for cocaine use compared with control subjects. The cocaine patients were recruited
from outpatient treatment programs in the province of Malaga (Spain) for a period of
24 months (August 2014 to August 2016). A total of 160 white Caucasian subjects were
recruited and divided into the cocaine group and the control group. To be eligible for the
study, participants had to be ≥18 years to 65 years of age. Exclusion criteria included a
personal history of the following: (1) chronic diseases (e.g., cardiovascular, respiratory,
renal, hepatic, neurological or endocrinological diseases); (2) cancer; (3) infectious diseases;
(4) incapacitating cognitive alterations; and (5) pregnancy for women.
Cocaine group and other dual diagnoses
Seventy-nine abstinent patients were diagnosed with CUD (cocaine abuse and/or
dependence). The diagnosis of CUD and other psychiatric disorders were performed with a
psychiatric interview (‘Diagnostic and Statistical Manual of Mental Disorders-4th Edition-
Text Revision’, DSM-IV-TR), while the abstinence from abused drugs was controlled
weekly by urine analysis in the outpatient treatment centers for cocaine addiction. Urine
analysis for cocaine, amphetamine, opiates, barbiturates, phencyclidine and cannabis was
performed using a V-Twin Drug Testing System (Siemens AG, Erlangen, Germany). These
data were used to select patients with CUD who abstained from abused drugs during the
last 2 weeks (at least). Subsequently, plasma analyses were conducted to verify cocaine
abstinence.
Control group without dual diagnosis
The control group was recruited from a multidisciplinary staff working at the Hospital
Regional Universitario de Málaga (Málaga, Spain). Eighty-one healthy and unmedicated
participants were matched to the cocaine group for age, sex and body mass index (BMI)
in order to provide reference values of circulating inflammatory factors. Subjects with
substance use disorders and past or current Axis I and Axis II disorders (DSM-IV-TR) and
neurologic disorders were excluded from the control group.
Ethics statement
Written informed consent was obtained from each participant after a complete description
of the study and after questions or issues were discussed. The study and protocols for
recruitment were approved by the Ethics Committee of the CEI Provincial de Málaga in
accordance with the ‘Ethical Principles for Medical Research Involving Human Subjects’
that was adopted in the Declaration of Helsinki by the World Medical Association (64th
WMA General Assembly, Fortaleza, Brazil, October 2013). The data were protected by
the Recommendation No. R (97) 5 of the Committee of Ministers to Member States on
the Protection of Medical Data (1997) and the Spanish data protection act (Ley Orgánica
15/1999 de Protección de Datos, LOPD).
Maza-Quiroga et al. (2017), PeerJ, DOI 10.7717/peerj.3926 4/20
Psychiatric evaluation
All patients with CUD were evaluated according to the DSM-IV-TR criteria using the
Spanish version of the ‘Psychiatric Research Interview for Substance andMental Disorders’
(PRISM 6.0) (Hasin et al., 1996; Torrens et al., 2004). Control subjects were initially
evaluated by PRISM to detect substance use disorders and by the Spanish version of ‘Dual
Diagnosis Screening Instrument’ (DDSI) to detect psychiatric disorders (DSM-IV-TR
Mestre-Pintó et al., 2014). All interviews were conducted by psychologists who had received
training certificates for these instruments.
PRISM
The PRISM diagnostic interview was used to assess psychopathological and substance use
disorders. PRISM is a semi-structured clinical interview designed to solve the problems
of diagnosis in people with consumption of substances and/or alcohol. This interview
presents good test-retest reliability, validity and inter-examiner reliability (kappa coefficient
oscillates between 0.66 and 1.00) (Morgello et al., 2006). The firstmodule contains questions
related to the history of consumption, ranging from the time of the diagnosis of abuse
and/or dependence. In addition, PRISM evaluates 20 Axis I disorders and 2 Axis II disorders
(borderline and antisocial personality disorders) according to DSM-IV-TR. The diagnoses
are performed using two time-frames: current (criteria were met within the past year)
and past (criteria were met before the previous 12 months). Consequently, the estimated
prevalence of a lifetime diagnosis would include both current and past diagnoses.
In addition, PRISM allows differentiation between primary mental disorders (or
independent disorders) and disorders induced by substances in combination with the
expected symptoms of the effect of intoxication and abstinence. The criteria established
by PRISM for a substance-induced disorder is that the disorder must occur in the context
of a pathological consumption of the substance in any of these 2 situations: (a) chronic
intoxication (consumption for four or more days a week for a month) and (b) binge
(consumption for a period of three continuous days) (Hasin et al., 1996; Torrens et al.,
2004).
The cocaine severity symptom was used to determine cocaine trait severity combining
the seven dependence criteria and the four abuse criteria (DSM-IV-TR) (Pavón et al., 2013;
Araos et al., 2015; Pedraz et al., 2015).
Collection of plasma samples for analysis
Blood samples were extracted in the morning (08:00–10:00 AM) after fasting for 8–12 h
and before the psychiatric interview. Venous blood samples were extracted into 10-mL K2
EDTA tubes (BD, Franklin Lakes, NJ, USA) and centrifuged at 2,200 g for 15 min (4 ◦C)
to obtain plasma. Plasma samples were individually assayed by three commercial tests for
detecting infectious diseases: HIV, hepatitis B and hepatitis C. Plasma analyses for cocaine
metabolite (Benzoylecgonine Specific Direct ELISA Kit purchased from Immunalysis Co.,
Pomona, CA, USA) were also performed to confirm cocaine abstinence. Plasma samples
were stored at −80 ◦C.
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Multiplex immunoassay analysis
For plasma determination, inflammatory proteins were chosen considering those
inflammatory factors that were not determined previously in abstinent cocaine patients
(see details in Araos et al., 2015). A Bio-Plex Suspension Array System 200 (Bio-Rad
Laboratories, Hercules, CA, USA) and ProcartaPlex Immunoassay Kit with magnetic beads
and an appropriate Plasma Standard Diluent Kit (eBioscience, Affymetrix, Santa Clara,
CA, USA) were used to quantify protein levels in the plasma. This method of analysis is
based on the Luminex technology, and a human cytokine 7-plex panel (Mix&Match Panel)
was used to simultaneously detect the following analytes: chemokine C-C motif ligand
11 (CCL11, eotaxin-1), interferon gamma (IFNγ), interleukin-4 (IL-4), interleukin-8
(IL-8), interleukin-17α (IL-17α), macrophage inflammatory protein 1α (MIP-1α) and
transforming growth factor α (TGFα).
The measurements of these analytes in plasma were performed following the
manufacturer’s instructions.
Statistical analysis
All clinical data in Tables 1 and 2 are expressed as the number and percentage of subjects
(N (%)) or the mean and SD (mean (SD)). The significance of differences in categorical
variables was determined using Fisher’s exact test (Chi-square test). The significance
of differences in normal continuous variables or non-normal continuous variables was
determined using Student’s t -test and Mann–Whitney U test, respectively. Statistical
analysis of protein levels was performed using multiple analysis of covariance (ANCOVA)
to indicate the relative effect of explanatory variables and their interactions on the protein
expression in the plasma, controlling for additional covariates. Log (10) transformation
was used to ensure statistical assumptions for positive skewed distributions. Estimated
marginal means (95% confidence intervals [95% CI]) of protein levels were expressed after
back-transformation as shown in Table 3 and Figs. 1 and 2.
In this study, we used the Kolmogorov–Smirnov test with Lilliefors correction to analyze
normality of data. We used Levene’s test to analyze homoscedasticity of the data.
All statistical analyses were performed using R-commander version 3.3.2 free software
and GraphPad Prism version 5.04 software (GraphPad Software, San Diego, CA, USA). A
p-value <0.05 was considered statistically significant. The specific statistical analysis used
is indicated in the text and in each figure caption.
RESULTS
Socio-demographic characteristics
The description of the socio-demographic variables of the participants is presented in
Table 1. A total of 160 subjects met the eligibility criteria for this study and were divided
into the cocaine (N = 79) and control (N = 81) groups.
The average age of the participants in the cocaine abstinent group was 35 years old, and
the average BMI was 26. We found significant differences between patients with CUD and
the controls in the marital status variable (p< 0.05). Cocaine patients had a significantly
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Table 1 Baseline socio-demographics and psychiatric characteristics in cocaine and control group.
Variable TotalN = 160
CocaineN = 79 ControlN = 81 p value
Age (mean(SD)) Years 34.87 (7.18) 37.27 (10.97) 0.115a
BMI (mean(SD)) Kg /m2 25.88 (4.20) 25.32 (3.65) 0.370b
Women 16 (20.25) 16 (19.75)
Sex (N(%))
Men 63 (79.75) 65 (80.25)
1c
Single 29 (36.71) 26 (47.3)
Married/Cohabiting 29 (36.71) 22 (40.0)
Divorced/separated 20 (25.32) 7 (12.7)
Marital status (N(%))
Widowed 1 (1.27) 0 (0.00)
0.004c
≤Primary/elementary 63 (79.75) 9 (11.11)
Education (N(%)) ≥Secondary 16 (20.25) 72 (88.89) <0.001
c
No 52 (65.82) 72 (88.89)
Psychiatric treatment (N(%))
Yes 27 (34.18) 9 (11.11)
<0.001c
No 34 (43.04)
Dual diagnosis (N(%))
Yes 45 (56.96)
–
–
No 21 (26.58)
Other substance use disorders (N(%))
Yes 58 (73.42)
–
–
Length of abstinence (mean (SD)) Days 133.4 (114.53) – –
Cocaine symptom severity (mean (SD)) (0–11)criteria 8.04 (2.66) – –
Notes.
BMI, body mass index.
ap-value from Student’s-test.
bp-value fromWilcoxon-test.
cp-value from Chi-square-test.
lower educational level and a higher percentage of psychiatric treatments compared with
the control group—(p< 0.001).
A total of 57% of cocaine patients were diagnosed with dual diagnosis, which includes
presenting with at least one psychiatric disorder throughout life (i.e., mood, anxiety,
psychotic or personality disorders (antisocial and borderline)). In addition, 73% of cocaine
patients were diagnosed with comorbid substance use disorders (e.g., alcohol, heroin,
cannabis, benzodiazepines, hallucinogens or other stimulants). The length of abstinence
from cocaine in these patients was 133 days, and the mean cocaine symptom severity was
8 CUD-criteria at the time of recruitment.
Plasma levels of inflammatory signaling proteins in subjects with
CUD and in controls
As shown in Fig. 1, the estimated marginal means of eotaxin-1, IFNγ, IL-4, IL-8, IL-17α,
MIP-1α and TGFα in the plasma are presented according to the history of cocaine use (the
cocaine and control groups). The plasma concentrations of these factors were analyzed by
ANCOVA using ‘cocaine use’ as the main factor and controlling for age, sex and BMI.
We found a significant main effect of ‘cocaine use’ on plasma levels of IL-17α
–(F1,133 = 20.713, p < 0.001), MIP-1α –(F1,147 = 26.444, p < 0.001) and TGFα –
(F1,540= 5.251, p< 0.05). Thus, cocaine patients showed lower levels of these inflammatory
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Figure 1 Cocaine vs. control group. Plasma levels of eotaxin-1 (CCL11), IFNγ, IL-4, IL-8, IL-17α, MIP-
1α and TGFα in abstinent patients with CUD (cocaine group) and control subjects (control group). Bars
are estimated marginal means and 95% CI (pg/mL). Data were analyzed by ANCOVA and (*) p < 0.05
and (***) p< 0.001 denote significant main effect of ‘cocaine use’, respectively.
Full-size DOI: 10.7717/peerj.3926/fig-1
proteins than the control group. In contrast, we found no differences between both groups
in the levels of eotaxin-1, IFNγ, IL-4 or IL-8.
Impact of psychiatric comorbidity on plasma levels of inflammatory
signaling proteins in subjects with CUD
Cocaine patients were divided into subgroups according to the diagnosis of psychiatric
comorbidity. Additionally, we used two different criteria of classification to explore the
effects of psychiatric comorbidity on these inflammatory factors: (a) Diagnosis of comorbid
substance use disorders and (b) Dual diagnosis with other mental health disorder(s). A
description of these patients is shown in Table 2.
A first classification of the cocaine group was performed according to the diagnosis of
other substance use disorders (yes (N = 58); no (N = 21)). The comparison between both
subgroups showed that there were no significant differences in age, BMI, sex, psychiatric
treatment, age of cocaine initiation or length of abstinence. However, we found significant
differences in the cocaine symptom severity –(p< 0.001), and patients with comorbid
substance use disorders had higher cocaine severity than patients with no other substance
use disorders (8.4 vs. 7.0 criteria). Although patients with substance use disorders had
an elevated prevalence of dual diagnosis (64%) compared with patients with no other
substance use disorders (38%); however, this difference did not reach statistical significance
(p= 0.075).
An additional classification was performed according to the detection of dual diagnosis
(yes (N = 45); no (N = 34)). We found no differences in BMI, sex, psychiatric treatment,
age of cocaine initiation or length of abstinence. In this case, we observed significant
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Table 2 Baseline socio-demographic variables and psychiatric characteristics in substance use disorders and dual diagnosis.
Variable CocaineN = 79
Other
substance
use disorders
Other
substance
use disorders
p value Dual
diagnosis
Dual
diagnosis
p value
Yes No Yes No
Participants (N (%)) 58 (73.42) 21 (26.58) – 45 (56.96) 34 (43.04) –
Age (mean (SD)) Years 34.72 (7.15) 35.29 (7.42) 0.726b 36.53 (6.65) 32.68 (7.18) 0.025b
BMI (mean (SD)) kg /m2 25.58 (3.41) 26.70 (5.89) 0.300a 26.58 (4.61) 24.95 (3.43) 0.089a
Women 10 (17.24) 6 (28.58) 11 (24.44) 5 (14.71)
Sex (N (%))
Men 48 (82.76) 15 (71.43)
0.430c
34 (75.56) 29 (85.29)
0.433c
No 37 (63.79) 15 (71.43) 26 (57.78) 26 (76.47)Psychiatric treatment
(N(%)) Yes 21 (36.21) 6 (28.58)
0.716c
19 (42.22) 8 (23.53)
0.135c
Age of cocaine initiation
(mean (SD))
Years 26.48 (8.12) 28.90 (7.47) 0.236a 26.42 (7.86) 28.06 (8.16) 0.507b
Length of abstinence
(mean (SD))
Days 139.50 (113.20) 116.30 (119.26) 0.287b 133.5 (102.68) 133.2 (130.19) 0.334b
Cocaine symptom
severity (mean (SD))
(0–11)criteria 8.41 (2.56) 7.00 (2.70) <0.001b 9.20 (1.65) 6.50 (2.97) <0.001b
No 21 (36.21) 13 (61.90)
Dual diagnosis (N (%))
Yes 37 (63.79) 8 (38.10)
0.075c
– – –
No 8 (17.78) 13 (39.24)Other substance use
disorders (N (%)) Yes
– –
–
37 (82.22) 21(61.76)
0.075c
Notes.
BMI, body mass index.
ap-value from Student’s-test.
bp-value fromWilcoxon-test.
cp-value from Chi-square-test.
differences in age (p< 0.05) and in the cocaine symptom severity (p< 0.001). Further,
patients with dual diagnosis were older (36.5 vs. 32.7 years) and had a more severe form of
CUD (9.2 vs. 6.5 criteria) than patients with no dual diagnosis. Furthermore, these patients
with dual diagnosis had an increased prevalence of comorbid substance use disorders
(82%) relative to patients with no dual diagnosis (62%), but this difference did not quite
reach statistical significance (p= 0.075).
Impact of dual diagnosis on plasma levels of inflammatory signaling
proteins in subjects with CUD
Figure 2 shows the estimated marginal means of eotaxin-1, IFNγ, IL-4, IL-8, IL-17α,
MIP-1α and TGFα in the plasma of cocaine patients, who were grouped according to the
presence of dual diagnosis. The plasma concentrations of these inflammatory markers were
analyzed by ANCOVA using ‘dual diagnosis’ as the main factor and controlling for age,
sex and BMI.
There was a significant main effect of ‘dual diagnosis’ on the plasma levels of TGFα
–(F1,190= 6.812, p< 0.05). Thus, cocaine patients with dual diagnosis showed lower TGFα
levels than patients with no dual diagnosis. Consequently, the presence of dual diagnosis
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Figure 2 Dual diagnosis yes vs. dual diagnosis no. Plasma levels of eotaxin-1 (CCL11), IFNγ , IL-4, IL-8,
IL-17α, MIP-1α and TGFα in the cocaine group according to dual diagnosis. Bars are estimated marginal
means and 95% CI (pg/mL). Data were analyzed by ANCOVA and (*) p < 0.05 denotes significant main
effect of ‘dual diagnosis’.
Full-size DOI: 10.7717/peerj.3926/fig-2
Table 3 Cocaine symptom severity on plasma levels of inflammatory signaling proteins.
Variable Concentration (pg/mL) (mean (SD))
Eotaxin-1 IFNγ IL-4 IL-8 IL-17α MIP-1α TGFα
Mild/moderate
(0–8)criteriaa
N = 38
35.16 (1.09) 2.13 (1.26) 1.38 (1.37) 4.02 (1.08) 0.27 (1.21) 1.88 (1.19) 1.71 (1.46)
Severe
(9–11)criteriaa
N = 41
38.46 (1.09) 2.47 (1.25) 1.45 (1.41) 4.04 (1.08) 0.35 (1.21) 1.96 (1.19) 0.95 (1.70)
p valueb 0.405 0.604 0.908 0.949 0.280 0.837 0.315
Notes.
aBased on DSM-IV-TR abuse and dependence criteria.
bP-value from ANCOVA analysis. It denotes significant differences when it is <0.05.
in the cocaine group enhanced a decrease in TGFα levels relative to the levels in the
control group.
Impact of cocaine symptom severity on plasma levels of
inflammatory signaling proteins in subjects with CUD
Because we observed significant differences in the cocaine symptom severity when cocaine
patients were grouped according to psychiatric comorbidity (comorbid substance use
disorders and dual diagnosis), we explored the impact of the degree of cocaine severity on
these circulating inflammatory proteins. Therefore, the cocaine group was divided into 2
subgroups as follows: mild/moderate ((0–8 criteria) N = 38) and severe ((9–11 criteria)
N = 41) CUD.
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Similar to previous analyses, plasma concentrations of these proteins were analyzed by
ANCOVA using ‘cocaine severity’ as the main factor and controlling for age, sex and BMI.
However, as shown in Table 3, we found no differences between both subgroups.
DISCUSSION
The search for potential biomarkers might enable a better stratification of patients to
establish therapeutic subgroups. These biomarkersmight arise from the activity of biological
systems involved in the pathogenesis ofmental disorders. There is evidence that the immune
system plays an important role in the pathogenesis of mental disorders and might be a
source for diagnostic biomarkers relevant for the treatment of addictive disorders and
associated psychiatric diseases (Fox et al., 2012; Araos et al., 2015; García-Marchena et al.,
2017a; García-Marchena et al., 2017b). In the present study, we attempted to establish
potential biomarkers of cocaine consumption and/or comorbid mental disorders by
identifying certain, cytokines, chemokines and growth factors in the plasma of patients
with these disorders. Previous studies (Araos et al., 2015; Pedraz et al., 2015) have revealed
that the circulatory/immune system-related signal or growth factors are associated with
CUD. The present results extend these observations and indicate that IL-17α, MIP-1α and
TGFα are altered in subjects diagnosed with CUD during abstinence, although there was
no association with the cocaine symptom severity, and that TGFα levels are also influenced
by the presence of dual diagnosis. Although certain studies revealed positive associations
between cytokines, chemokines, circulating growth factors and CUD (Sáez et al., 2011;
Levandowski et al., 2016; Scherer et al., 2016), other studies reported a decreased expression
of inflammatory proteins in CUD patients.
For instance, cocaine abusers were found to have decreased IL-10 levels compared with
the levels found in social drinkers (Fox et al., 2012), and cocaine-dependent volunteers
showed a decrease in the expression of cytokines such as TNFα and IL-6 (Irwin et al.,
2007). Therefore, the role of these inflammatory signals in the neurobiology of addiction
is not yet fully understood.
Cytokines and other inflammatory mediators are produced by several types of cells,
mainly immune cells (e.g., lymphocytes and macrophages), and act through receptors in
the regulation of crucial processes such as inflammation and embryogenesis. Some of these
signals can cross the blood brain barrier and produce an inflammatory state that has been
linked to dysfunctions on ascending monoaminergic systems (Petrulli et al., 2017). In fact,
cytokines and their receptors are expressed in microglia, which are immune cells present in
the brain that participate in processes such as remodeling and synaptic pruning (Paolicelli
et al., 2011), as well as in astrocytes and neurons.
The decreased plasma levels of IL-17α, MIP-1α and TGFα are similar to that described in
the same population for other cytokines and chemokines such as TNFα, MCP-1 and SDF-1
(Araos et al., 2015). Although cocaine has been described to produce a pro-inflammatory
state, the decrease in the levels of IL-17α, MIP-1α and TGFα can be interpreted as
a compensatory effect that reduces the cocaine-induced inflammatory tone along the
period of abstinence in comparison with control subjects. A similar phenomenon has
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been described for certain growth factor in our outpatient cohort of cocaine patients
(Pedraz et al., 2015). However, none of the proteins that were analyzed in the present study
were associated with CUD severity, unlike our previously described findings with IL-1β,
fractalkine or SDF-1 as severity-sensitive factors (Araos et al., 2015).
As currently described in the literature, IL-17α plays a key role in autoimmune diseases
in the CNS, such as multiple sclerosis (Zimmermann et al., 2017). However, there are no
studies showing that IL-17α is involved in the effects of cocaine or other abused drugs.
Regarding MIP-1α, this chemokine contributes to the modulation of immune responses,
and MIP-1α is believed to be important in the pathogenesis of autoimmune and infectious
diseases, as well as cancer (Snyder-Cappione et al., 2010). Recently, we have described that
concentrations ofMIP-1α aremildly affected in patients with alcohol use disorders (García-
Marchena et al., 2017a). Although there is no scientific evidence linking this chemokine
to the neuropharmacology of cocaine, it has been described that cocaine use activates
the release of MIP-1α and promotes opening of the blood brain barrier, facilitating not
only neuroinflammation but also viral infection from drug injectors (Zhang et al., 1998).
Considering that neurobiological changes associated with peripheral inflammatory states
facilitate the action of psychostimulants (Petrulli et al., 2017), this clear association between
MIP-1α and cocaine use demands further neurobiological studies.
It has been discovered that TGFα is related to a number of diseases. This ligand of the
epidermal growth factor receptor has been proposed as a prognostic biomarker for gastric
carcinoma (Fanelli et al., 2012), also for melanoma (Tarhini et al., 2014). Concerning CNS,
TGFα is related to neurogenesis (Cooper & Isacson, 2004) and the decrease of TGFα in the
plasma of cocaine patients might be related to a decrease in neurogenesis, which has been
reported after acute administration of cocaine in animal models (Blanco-Calvo et al., 2014).
This inhibition of neurogenesis might be associated with persistent rewarding memories
for cocaine, and therefore, a decreased expression of TGFα might facilitate the persistence
of cocaine abuse (Deschaux et al., 2014). Additionally, genetic models lacking TGFα in the
brain result in super sensitivity to the psychostimulant effect of cocaine in a manner similar
to that described for inflammation (Stanwood & Levitt, 2007). However, although a study
in a population with heroin abuse disorders shows elevated levels of TGFα in injecting
drug users with active consumption (Piepenbrink et al., 2016), to our knowledge, there are
no studies relating TGFα to CUD.
Over the last decade, a growing number of studies have explored the potential role
of cytokines, chemokines and growth factors in populations with mental disorders
(Raison, Capuron & Miller, 2006; Ogłodek et al., 2015; Van Varsseveld et al., 2015; Engler
et al., 2017; Michopoulos et al., 2017; Notter et al., 2017) and/or drug addiction, including
CUD (Irwin et al., 2007; Parikh et al., 2014; Levandowski et al., 2016). Thus, certain studies
have found reduced circulating cytokines in patients with generalized anxiety before and
afterMindfulness treatment, when compared to their controls (Hoge et al., in press). Plasma
levels of IL-17 and IL-23 are altered in schizophrenic patients relative to the levels in their
controls (Li et al., 2016). Additionally, longitudinal studies described how personality traits
predict IL-6 levels (Turiano et al., 2013).
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An increase in IL-1β levels has been observed in patients with CUD with dual diagnosis
compared to patients with CUD without a dual diagnosis (Araos et al., 2015). We believe
that, togetherwithmonitoring cytokines, chemokines and growth factors, it is also necessary
to characterize these patients with and without dual diagnosis, since they are patients with
different therapeutic needs and approaches (Balhara, Kuppili & Gupta, 2017).
Related to the above, TGFα emerges as the only signal associated with both CUD and
dual diagnosis. To our knowledge, there is no scientific literature on the relationship
between CUD, dual diagnosis and plasma levels of TGFα.
In any case, the evaluation and validation of TGFα as a suitable candidate for a potential
biomarker of bothCUDanddual diagnosis could opennew research lines for understanding
the complexities of cocaine addiction and the associated dual diagnosis.
The evaluation of cytokines, chemokines and growth factors in plasma could improve
the stratification of CUD patients undergoing treatment and complement therapeutic
interventions, including the high risk of dual diagnosis. Additional studies would be
needed to examine new molecules of the immune system in order to elucidate their role in
the etiology of CUD.
Several limitations should be considered when discussing the present findings. First,
larger studies are needed because variability is common when considering the association
of immune signals with mental disorders. As an example, a meta-analysis of depressive
patients with matched controls and their relationship with circulating levels of plasma
cytokines shows that there is a considerable heterogeneity of results (Köhler et al., 2017).
Second, it would also be necessary to include samples of depressed or anxious patients
with no diagnosis of substance use disorders throughout life in order to compare CUD
populations with or without dual diagnosis. Third, the small number of female patients is
an important limitation of the present study. It would be necessary to increase the sample
population of women in order to have a more comprehensive view of the results obtained.
Fourth, it would be interesting to include in future studies subjects with active cocaine
consumption to observe the effects of the presence of cocaine at circulating levels. It would
also be necessary to control the pathway of confounding pharmacological treatment; as
such, controlling themedical use of anti-depressants, anxiolytics and anti-psychotics would
give more consistency to the current findings.
Finally, there is a need for integrating all the information concerning this multiplicity of
inflammatory signals in a singlemodel of cocaine addiction. Although certain factors such as
TGFαmight contribute to important aspects of cocaine addiction and associated psychiatric
comorbidities, the complexity of the interactions of these signaling inflammatory proteins
falls beyond our current understanding. Further basic and clinical research is needed to
elucidate the role of TGFα and other factors in the pathogenesis of addiction and their
utility as potential clinical biomarkers.
We conclude from this study that TGFα could be a potential biomarker of CUD and
dual diagnosis in abstinent patients; moreover, additional studies are needed to investigate
and validate the effects of TGFα in patients with CUD.
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